TABLE 4.
Application of oncolytic viruses in the treatment of ovarian cancer.
| Virus type | Study | Virus | N | Phase | Status | Method of administration | Population |
|---|---|---|---|---|---|---|---|
| Measles virus | NCT00408590 | MV-CEA virus & MV-NIS virus | 37 | I | Completed | Intraperitoneal | Progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer |
| NCT02068794 | MV-NIS infected mesenchymal stem cells | 57 | I/Ⅱ | Recruiting | Intraperitoneal | Recurrent ovarian cancer | |
| NCT02364713 | MV-NIS | 66 | Ⅱ | Recruiting | - | Platinum-resistant ovarian, recurrent ovarian carcinoma | |
| Adenovirus | NCT02028117 | Enadenotucirev | 38 | I | Completed | Intraperitoneal | Platinum-resistant epithelial ovarian cancer |
| NCT05180851 | Recombinant L-IFN adenovirus injection | 28 | Ⅰ | Recruiting | Even injection of the drug solution into the tumor edge | Relapsed/refractory solid tumors | |
| NCT03225989 | LOAd703 | 50 | I/Ⅱ | Recruiting | Intratumoral image-guided injections | Pancreatic cancer, biliary cancer, ovarian cancer and colorectal cancer | |
| NCT05271318 | TILT-123 | 15 | I | Recruiting | - | Platinum-resistant or refractory ovarian cancer | |
| NCT00964756 | Ad5.SSTR/TK.RGD | 11 | Ⅰ | Completed | Intravenous | Recurrent ovarian cancer | |
| NCT00562003 | Ad5-Delta 24 RGD | 26 | Ⅰ | Completed | Intraperitoneal | Ovarian cancer, primary peritoneal cancer | |
| NCT00002960 | SCH 58500 (rAd/p53) | 59 | Ⅰ | Completed | Single intraperitoneal instillation | Primary ovarian, fallopian tube, or peritoneal cancer | |
| NCT00003880 | SCH 58500 (rAd/p53) | 132 | Ⅱ/Ⅲ | Terminated | Intraperitoneal | Newly diagnosed stage III ovarian or stage III primary peritoneal cancer with residual disease following surgery | |
| NCT02963831 | ONCOS-102 | 67 | Ⅰ/Ⅱ | Completed | Intraperitoneal infusion | Peritoneal disease for which prior standard chemotherapy has failed and histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer | |
| Vaccinia virus | |||||||
| NCT02017678 | JX-594 | 0 | Ⅱ | Withdrawn | Intravenous | Peritoneal carcinomatosis of ovarian origin in which patients are not eligible for curative treatments | |
| NCT02759588 | GL-ONC1 | 64 | I/Ⅱ | Active, not recruiting | Intraperitoneal | Recurrent or refractory ovarian cancer | |
| NCT05281471 | GL-ONC1 (Olvi-Vec) | 186 | Ⅲ | Recruiting | Intraperitoneal catheter infusions | Platinum-resistant/refractory ovarian cancer | |
| NCT05051696 | H101 | 60 | _ | Recruiting | Intratumor injection | Refractory/recurrent gynecological malignancies | |
| NCT05061537 | PF-07263689 | 10 | Ⅰ | Active, not recruiting | Intravenous | Ovarian cancer for which all available standard-of-care therapies have been exhausted | |
| Reolysin | NCT01199263 | Pelareorep | 108 | Ⅱ | Completed | Intravenous | Recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer |